Sunshine Heart (NASDAQ:CHFS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Friday.

According to Zacks, “CHF Solutions, Inc. is a medical device company which focused on commercializing the Aquadex FlexFlow (R) System. Its commercial product Aquadex system, is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. CHF Solutions Inc., formerly known as Sunshine Heart Inc., is headquartered in Minneapolis. “

Separately, ValuEngine cut Sunshine Heart from a “sell” rating to a “strong sell” rating in a research report on Monday, October 2nd.

Shares of Sunshine Heart (NASDAQ:CHFS) traded up $0.01 during midday trading on Friday, hitting $3.52. The company had a trading volume of 172,933 shares, compared to its average volume of 139,775. Sunshine Heart has a 52 week low of $2.87 and a 52 week high of $220.60. The company has a market capitalization of $6.31, a PE ratio of -0.02 and a beta of 2.25.

In related news, major shareholder Ki Yong Choi purchased 61,645 shares of the firm’s stock in a transaction that occurred on Thursday, October 12th. The shares were bought at an average price of $0.52 per share, for a total transaction of $32,055.40. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 2.00% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION NOTICE: This piece was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/05/sunshine-heart-chfs-rating-lowered-to-hold-at-zacks-investment-research.html.

About Sunshine Heart

CHF Solutions, Inc, an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. It focused on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.

Get a free copy of the Zacks research report on Sunshine Heart (CHFS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sunshine Heart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Heart and related companies with MarketBeat.com's FREE daily email newsletter.